Key Takeaways Lilly's Mounjaro and Zepbound drive half its revenues, fueling over 30% expected 2025 sales growth.AbbVie rebounds post-Humira LOE with Skyrizi and Rinvoq, targeting $25B in combined 2025 sales.2025 estimates for Lilly indicate 37% sales and 76.7% EPS growth, outpacing AbbVie's 7.6% and 18.9%.Eli Lilly (LLY) and AbbVie (ABBV) are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint. Bo ...

With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts As part of its $10 billion U.S. capital expenditure strategy to increase biologics manufacturing capacity, AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its AbbVie Bioresearch Centre in Worcester, M ...

With many stocks looking overvalued, many investors may be tempted to sell. However, there are several factors to consider before taking profits: Time horizon – when an investor will need the money The availability of better alternative investments Tax ramifications from taking short-term or long-term gains This article only focuses on the first factor. For long-term investors, time is almost always an ally. But that depends on the stock. Blue-chip stocks come to mind. The companies behind these stocks ar ...

(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie said in a regulatory filing that such expenses may arise from collaborations, licensing deals or asset buys, but are not forecast due to uncertainty around timing and occurrence. It did not ...

AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. Pixabay/Public Do ...

AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside. Today’s Featured Stock Valued at $394 billion, AbbVie (ABBV) has become one of the top-most phar ...

Summary of Option Care Health Conference Call Company Overview - **Company**: Option Care Health (NasdaqGS: OPCH) - **Industry**: Home and alternate site infusion therapy - **Key Facts**: - Largest provider of infusion services in the U.S. - Serves over 300,000 unique patients annually - Employs approximately 8,000 team members, with over 4,000 being clinicians - Licensed in all 50 states with over 90 pharmacies for compounding and distribution [4][5] Core Business Insights - **Service Focus**: High-quality care at an appropriate cost, addressing the high cost of healthcare while maintaining clinical outcomes [5][7] - **Market Demand**: Strong relationships with referral sources (hospitals, clinics) to capture demand across acute and chronic portfolios [5][6] - **Growth Drivers**: - High single-digit organic top-line growth and low double-digit adjusted EBITDA growth expected to continue [9][10] - Combination of low single-digit growth in acute care and faster-growing low double-digit growth in chronic care [10] Financial Performance - **Revenue Growth**: Anticipated growth driven by innovation, new disease prevalence, and partnerships with pharmaceutical companies [10][11] - **Gross Profit**: Expected to grow at a slower rate than revenue due to a mix shift towards chronic care, but still contributing positively to gross margin [11] - **Adjusted EPS**: New disclosures indicate expected growth in adjusted EPS due to strong cash generation [12] Market Dynamics - **Private Equity Activity**: Increased interest in home infusion services, indicating a competitive and capital-rich environment [6] - **Biosimilars**: Seen as an opportunity for upside, providing leverage for better acquisition costs despite lower margins [29][30] Challenges and Risks - **Stelara Drug Economics**: Expected impact of $60-70 million in 2025 due to changes in reimbursement and inventory management [21][24] - **Market Share**: Despite strong performance, there is still market share to capture, requiring ongoing local execution and partnerships [13][14] Strategic Initiatives - **Advanced Practitioner Model**: Aimed at expanding access for Medicare beneficiaries and enhancing clinical oversight for complex patients [33][36] - **M&A Strategy**: Focused on disciplined capital deployment for growth, with potential acquisitions to enhance market presence [43][44] Future Outlook - **Growth Expectations**: Anticipated reversion to historical growth rates post-competitive exits, with continued focus on capturing market demand [41] - **Cash Flow Generation**: Projected over $320 million in cash flow from operations, providing opportunities for shareholder-friendly capital deployment [45][46] Conclusion - **Execution Capability**: The company emphasizes its ability to execute consistently and maintain a durable business model, positioning itself well for future growth [45][46]

Group 1 - Companies that consistently raise dividends have outperformed the S&P 500 by 2.5 percentage points annually since 1972, with a $10,000 investment in dividend growers in 1972 now worth over $4 million compared to $1.6 million in the S&P 500 [2] - Five blue-chip companies exemplify the strategy of combining current income with dividend growth, contributing to wealth accumulation [3] Group 2 - AbbVie (NYSE: ABBV) has a dividend yield of 2.97% and has raised its dividend for 12 consecutive years, despite facing a significant patent cliff with Humira, with a payout ratio of 303% that is distorted by acquisition accounting [4][5] - Costco (NASDAQ: COST) has a low yield of 0.57% but boasts a 13.2% annual dividend growth rate over the past five years, with a conservative payout ratio of 27%, and its membership fees could cover the entire dividend [6][7] - American Express (NYSE: AXP) offers a 0.92% yield but has compounded its dividend at 12% annually over the past five years, with only 21.3% of earnings allocated to dividends, controlling both card issuance and payment processing [10] Group 3 - The combined shareholder returns of these five companies exceed $500 billion over the past decade, with dividend growth every year, and yields ranging from 0.57% at Costco to 7.2% at Pfizer, catering to both income and growth-focused investors [9]

Core Insights - Investors are taking a bearish stance on AbbVie, with significant options activity indicating potential insider knowledge of upcoming events [1][2] - The overall sentiment among large investors is slightly bearish, with 54% bearish and 45% bullish positions [2] - Significant investors are targeting a price range of $160.0 to $220.0 for AbbVie over the past three months [3] Options Activity - In the last 30 days, 11 uncommon options trades were identified for AbbVie, with 9 puts totaling $807,896 and 2 calls totaling $67,330 [2][4] - Detailed analysis of options activity shows a focus on bearish trades, with notable put options indicating a lack of confidence in the stock's near-term performance [9] Company Overview - AbbVie is a pharmaceutical company with strong exposure to immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions in neuroscience and oncology [10] - Analysts have provided a range of target prices for AbbVie, with an average target of $247.4, and individual targets ranging from $222 to $270 [12][13] Market Performance - AbbVie’s current trading volume stands at 2,435,721, with the stock price at $220.44, reflecting a 0.87% increase [15] - The stock may be approaching overbought conditions, with an earnings announcement expected in 33 days [15]

Key Takeaways AbbVie projects revenue growth in 2025 despite Humira sales falling by over 54% in the first half of 2025.Skyrizi and Rinvoq are fueling gains with new launches, head-to-head data and expanding indications.AbbVie is also expanding in oncology and neuroscience, adding new drugs and boosting migraine uptake.AbbVie (ABBV) expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent i ...